Indiana University Health Physicians started as the Indiana Clinic three years ago with plans to employ at least 1,200 physicians by now. That hasn’t happened, but the organization said it won’t stop folding doctors into its organization.
For the first time in three years, Bioanalytical Systems Inc. boosted its annual revenue. But instead of receiving congratulations, one of the company’s largest shareholders said the company’s trends are “bleak.”
Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.
A federal judge has dismissed a shareholder class-action lawsuit against WellPoint stemming from the company’s 2001 conversion from a mutual insurer to a publicly traded company.
It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
It looks like Arcadia Resources Inc.’s DailyMed pharmacy business will live on—but under the wing of Walgreen Co. instead of on its own.
YMCA of Greater Indianapolis officials have started a $40 million fundraising campaign that will be used to fund three more local locations, including a much-delayed $10 million facility in Pike Township.
It will be difficult to rebrand the arena where the Indiana Pacers play, but team officials praised sponsor CNO Financial for sticking with the $20 million naming-rights deal despite tough times.
Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.
Officials say an as-yet-unnamed drug company is looking to take over much of the former Pfizer Inc. complex near Terre Haute that had about 800 workers before it was shut down.
The Pacers have not announced a name change, but have a special announcement scheduled for Thursday.
The Indianapolis-based partnership is among 32 in the U.S. chosen for a model program designed to provide more coordinated care for people served by Medicare.
As it is in the rest of the country, the 2010 health reform in Indiana continues to be unpopular, unlikely to be repealed and uncertain to put a dent in health spending, according to a poll of Hoosiers released last week by Ball State University.
Franciscan Alliance’s Indianapolis-area hospitals, along with more than 700 physicians, have been named one of the nation’s first 32 accountable care organizations.
A federal agency will reconsider whether Indiana violated federal law when it decided to cut off Medicaid funding to Planned Parenthood and other abortion providers.
Independent health care facilities, like Body One Physical Therapy, are seeing referrals from physicians beginning to slacken as more and more doctors become employees of hospitals. The hospitals request that doctors send patients to their in-house physical therapy practices.
The new hires could be important following last year’s legislative session, in which state lawmakers passed a law to cut off Medicaid funding to groups that offer abortions.
Pharmacy benefits manager Express Scripts Inc. said Tuesday it is in the middle of a contract dispute with WellPoint Inc., one of the biggest health insurers in the United States.
Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
